218 related articles for article (PubMed ID: 32083571)
1. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations.
Geng H; Li S; Guo Y; Yan F; Han Y; Xu M; Cui Y
Cancer Biomark; 2020; 27(4):525-532. PubMed ID: 32083571
[TBL] [Abstract][Full Text] [Related]
2. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
Wang Z; Chen X
Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
[TBL] [Abstract][Full Text] [Related]
3. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
4. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
5. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
8. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
[TBL] [Abstract][Full Text] [Related]
10. LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features.
Yu J; Hu Y; Xu Y; Wang J; Kuang J; Zhang W; Shao J; Guo D; Wang Y
BMC Cancer; 2019 Mar; 19(1):263. PubMed ID: 30902072
[TBL] [Abstract][Full Text] [Related]
11. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.
Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X
Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701
[TBL] [Abstract][Full Text] [Related]
12. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis.
Zhang MY; Liu XX; Li H; Li R; Liu X; Qu YQ
Int J Med Sci; 2018; 15(14):1676-1685. PubMed ID: 30588191
[No Abstract] [Full Text] [Related]
13. A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model.
Sun N; Chu J; Hu W; Chen X; Yi N; Shen Y
Sci Rep; 2022 Jan; 12(1):27. PubMed ID: 34996932
[TBL] [Abstract][Full Text] [Related]
14. Survival prediction model for non-small cell lung cancer based on somatic mutations.
Zhang W; Lin X; Li X; Wang M; Sun W; Han X; Sun D
J Gene Med; 2020 Sep; 22(9):e3206. PubMed ID: 32367667
[TBL] [Abstract][Full Text] [Related]
15. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
16. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
[TBL] [Abstract][Full Text] [Related]
17. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Proliferation-Associated Score Model Predicting Survival in Lung Adenocarcinomas.
Bian Y; Sui Q; Bi G; Zheng Y; Zhao M; Yao G; Xue L; Zhang Y; Fan H
Dis Markers; 2021; 2021():3219594. PubMed ID: 34721732
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
[TBL] [Abstract][Full Text] [Related]
20. Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma.
Li YY; Yang C; Zhou P; Zhang S; Yao Y; Li D
J Cell Biochem; 2018 Nov; 119(11):8909-8921. PubMed ID: 30105759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
